E-LIB Suche - Ergebnisse für: Pour, Luděk

1

PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen ..:

Pour, Ludek ; Micheva, Ilina ; Usenko, Ganna...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 6 - p. e267-e275.e2 , 2024

Link: https://doi.org/10.1016/..

2

Ixazomib plus daratumumab and dexamethasone: Final analysis..:

Delimpasi, Sosana ; Dimopoulos, Meletios A. ; Straub, Jan...
American Journal of Hematology. , 2024

Link: https://doi.org/10.1002/..

3

Health-related quality of life in relapsed/refractory multi..:

Schjesvold, Fredrik H. ; Ludwig, Heinz ; Delimpasi, Sossana...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

4

An open‐label, first‐in‐human, single agent, dose escalatio..:

Kapoor, Prashant ; Nathwani, Nitya ; Jelinek, Tomas...
European Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

5

Patient Characteristics, Treatment Patterns, and Outcomes i..:

Maisnar, Vladimir ; Pour, Ludek ; Spicka, Ivan...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 2 - p. 145-153 , 2023

Link: https://doi.org/10.1016/..

6

Isatuximab, carfilzomib, and dexamethasone in patients with..:

Martin, Thomas ; Dimopoulos, Meletios-Athanasios ; Mikhael, Joseph...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

7

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DAR..:

Miguel, Enrique Maria Ocio San ; Efebera, Yvonne A. ; Hájek, Roman...
HemaSphere. 7 (2023) S3 - p. e2842627 , 2023

Link: https://doi.org/10.1097/..

8

OA-48 Isatuximab plus carfilzomib and dexamethasone versus ..:

Yong, Kwee ; Martin, Thomas ; Dimopoulos, Meletios...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S30-S31 , 2023

Link: https://doi.org/10.1016/..

9

Improved Screening of Monoclonal Gammopathy Patients by MAL..:

Pečinka, Lukáš ; Vlachová, Monika ; Moráň, Lukáš...
Journal of the American Society for Mass Spectrometry. 34 (2023) 12 - p. 2646-2653 , 2023

Link: https://doi.org/10.1021/..

10

Efficacy and safety of melflufen plus daratumumab and dexam..:

Pour, Luděk ; Szarejko, Monika ; Bila, Jelena...
Haematologica. 109 (2023) 3 - p. 895-905 , 2023

Link: https://doi.org/10.3324/..

11

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLA..:

Popková, Tereza ; Pour, Ludek ; Spicka, Ivan...
HemaSphere. 7 (2023) S3 - p. e0151603 , 2023

Link: https://doi.org/10.1097/..

12

P-159 Lenalidomide maintenance in R2-ISS stratified multipl..:

Radocha, Jakub ; Jungova, Alexandra ; Pour, Ludek...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S122-S123 , 2023

Link: https://doi.org/10.1016/..

13

Correction: Isatuximab, carfilzomib, and dexamethasone in p..:

Martin, Thomas ; Dimopoulos, Meletios-Athanasios ; Mikhael, Joseph...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

14

P-042 Early infections in myeloma patients treated with ant..:

Radocha, Jakub ; Pour, Ludek ; Jelinek, Tomas...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S57-S58 , 2023

Link: https://doi.org/10.1016/..

15

P-296 Lighthouse: melflufen, daratumumab, and dexamethasone..:

Mateos, Maria-Victoria ; Szarejko, Monika ; Bila, Jelena...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S200-S201 , 2023

Link: https://doi.org/10.1016/..